title: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
abstract: OBJECTIVE
  To determine if a therapeutic regimen of twice-weekly applications of mechlorethamine hydrochloride and betamethasone dipropionate cream is effective in the treatment of early-stage mycosis fungoides while increasing cutaneous tolerance.
  
  
  METHODS
  Prospective nonrandomized study conducted from November 1999 to November 2002.
  
  
  METHODS
  Eleven university or hospital dermatology departments in France.
  
  
  METHODS
  Sixty-four consecutive patients with newly diagnosed early-stage mycosis fungoides (stage IA, n = 33; stage IB, n = 26; stage IIA, n = 5).
  
  
  METHODS
  Patients were treated with twice-weekly applications of a 0.02% aqueous solution of mechlorethamine followed by an application of betamethasone cream during a 6-month period.
  
  
  METHODS
  The primary end point was the rate of complete response during the treatment. Secondary end points were mean delay to achieve complete response, rate of severe cutaneous reactions of intolerance, and rate of relapse after achieving complete response.
  
  
  RESULTS
  Thirty-seven patients (58%) had a complete response after a mean +/- SD treatment duration of 3.6 +/- 2.5 months: 20 (61%) of 33 patients with stage IA disease, 15 (58%) of 26 patients with stage IB disease, and 2 (40%) of 5 patients with stage IIA disease. Eighteen patients (28%) developed severe cutaneous reactions of intolerance that necessitated treatment discontinuation. Relapse was observed in 17 patients (46%) after a mean +/- SD time of 7.7 +/- 6.5 months.
  
  
  CONCLUSIONS
  A regimen of twice-weekly applications of mechlorethamine and betamethasone cream is an effective treatment for early-stage mycosis fungoides. The decreased frequency of applications provides an advantage to the patient by being easy to use with limited adverse effects.
authors.affiliation: Department of Dermatology and Pathology, University of Rouen, Rouen, France.
authors.forename: Julie
authors.initials: J
authors.lastname: de Quatrebarbes
authors.forename: Eric
authors.initials: E
authors.lastname: Estève
authors.forename: Martine
authors.initials: M
authors.lastname: Bagot
authors.forename: Philippe
authors.initials: P
authors.lastname: Bernard
authors.forename: Marie
authors.initials: M
authors.lastname: Beylot-Barry
authors.forename: Michele
authors.initials: M
authors.lastname: Delaunay
authors.forename: Michel
authors.initials: M
authors.lastname: D'Incan
authors.forename: Pierre
authors.initials: P
authors.lastname: Souteyrand
authors.forename: Loïc
authors.initials: L
authors.lastname: Vaillant
authors.forename: Nadège
authors.initials: N
authors.lastname: Cordel
authors.forename: Philippe
authors.initials: P
authors.lastname: Courville
authors.forename: Pascal
authors.initials: P
authors.lastname: Joly
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D001507:Beclomethasone / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D018906:Antineoplastic Agents, Alkylating; D005938:Glucocorticoids; D008466:Mechlorethamine; D001507:Beclomethasone